logo

For the Inventor, By the Inventor

Osaka, Japan

Motohiko Ueda

This inventor holds 5 USPTO granted patents. Top assignee: Shionogi Company Limited. Active years: 1978-1993.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Motohiko Ueda. Retrieved from https://idiyas.com/inventor/motohiko-ueda-lsqt49tq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 33(Granted Patents)


Location History:

  • Suita, JA (1978)
  • Osaka, JP (1985 - 1989)
  • Suita, JP (1993)

Company Filing History:

goldMedal5 out of 1,001 
 
Shionogi Company Limited
 patents

Years Active: 1978-1993

Loading Chart...
5 patents (USPTO):Explore Patents
1. 5242915 - Formulation useful for the inhibition of massive release of cerebral (1993-09-07),
2. 4873334 - 4,7-dihydropyrazolo(3,4-b) pyridine derivatives (1989-10-10),
3. 4703051 - 4,7-dihydrothieno[2,3-B]pyridine derivatives useful in the treatment of (1987-10-27),
4. 4562256 - 1,6-Dialkyl-3-su (1985-12-31),
5. 4085114 - 1,2-Benzoisoxazole derivatives and the production thereof (1978-04-18),

Title: Motohiko Ueda: Innovator in Pharmaceutical Formulations

Introduction

Motohiko Ueda is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of formulations aimed at treating neurological conditions. With a total of 5 patents to his name, Ueda's work has the potential to impact the lives of many individuals suffering from serious health issues.

Latest Patents

Ueda's latest patents include a formulation useful for the inhibition of massive release of cerebral glutamate. This method is particularly relevant for the treatment or prevention of diseases such as epilepsy and dementia. The pharmaceutical formulations he developed contain a therapeutically effective amount of methyl (+)-(4S)-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate (S-312-d). Another notable patent involves novel 4,7-dihydropyrazolo(3,4-b)pyridine derivatives, which serve as calcium blockers. These derivatives exhibit potent antihypertensive and coronary vasodilating actions, making them useful in treating diseases of the circulatory system without causing systolic inhibition.

Career Highlights

Motohiko Ueda is associated with Shionogi Company Limited, a well-respected organization in the pharmaceutical industry. His work at Shionogi has allowed him to focus on innovative solutions that address critical health challenges. Ueda's dedication to research and development has positioned him as a key figure in his field.

Collaborations

Ueda has collaborated with notable colleagues, including Ikuo Adachi and Teruo Yamamori. These partnerships have fostered an environment of innovation and have contributed to the advancement of their shared goals in pharmaceutical research.

Conclusion

Motohiko Ueda's contributions to the field of pharmaceuticals through his innovative patents highlight his commitment to improving health outcomes. His work continues to pave the way for advancements in treatments for neurological and circulatory conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…